Trade Prelude Therapeutics Incorporated - PRLD CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Prelude Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 3.18 |
| Open* | 3.07 |
| 1-Year Change* | -55.57% |
| Day's Range* | 2.93 - 3.11 |
| 52 wk Range | 1.66-8.57 |
| Average Volume (10 days) | 100.03K |
| Average Volume (3 months) | 3.69M |
| Market Cap | 177.03M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 96.78M |
| Revenue | N/A |
| EPS | -2.17 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Mar 13, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 4, 2023 | 3.18 | 0.03 | 0.95% | 3.15 | 3.26 | 3.06 |
| Dec 1, 2023 | 3.19 | 0.00 | 0.00% | 3.19 | 3.23 | 3.08 |
| Nov 30, 2023 | 3.28 | -0.02 | -0.61% | 3.30 | 3.43 | 3.24 |
| Nov 29, 2023 | 3.33 | 0.04 | 1.22% | 3.29 | 3.38 | 3.29 |
| Nov 28, 2023 | 3.29 | 0.11 | 3.46% | 3.18 | 3.34 | 3.18 |
| Nov 27, 2023 | 3.23 | -0.12 | -3.58% | 3.35 | 3.36 | 3.22 |
| Nov 24, 2023 | 3.28 | -0.05 | -1.50% | 3.33 | 3.40 | 3.20 |
| Nov 22, 2023 | 3.32 | 0.12 | 3.75% | 3.20 | 3.32 | 3.13 |
| Nov 21, 2023 | 3.21 | -0.09 | -2.73% | 3.30 | 3.34 | 3.18 |
| Nov 20, 2023 | 3.40 | -0.19 | -5.29% | 3.59 | 3.59 | 3.37 |
| Nov 17, 2023 | 3.56 | 0.27 | 8.21% | 3.29 | 3.58 | 3.29 |
| Nov 16, 2023 | 3.38 | 0.15 | 4.64% | 3.23 | 3.45 | 3.18 |
| Nov 15, 2023 | 3.36 | 0.26 | 8.39% | 3.10 | 3.67 | 3.10 |
| Nov 14, 2023 | 3.15 | 0.14 | 4.65% | 3.01 | 3.24 | 2.97 |
| Nov 13, 2023 | 2.98 | 0.10 | 3.47% | 2.88 | 3.15 | 2.88 |
| Nov 10, 2023 | 2.98 | 0.05 | 1.71% | 2.93 | 2.99 | 2.61 |
| Nov 9, 2023 | 3.00 | 0.06 | 2.04% | 2.94 | 3.02 | 2.93 |
| Nov 8, 2023 | 2.97 | -0.01 | -0.34% | 2.98 | 3.00 | 2.77 |
| Nov 7, 2023 | 2.98 | 0.09 | 3.11% | 2.89 | 3.03 | 2.73 |
| Nov 6, 2023 | 2.93 | 0.75 | 34.40% | 2.18 | 3.18 | 2.01 |
Prelude Therapeutics Incorporated Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, March 13, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q4 2023 Prelude Therapeutics Inc Earnings Release Q4 2023 Prelude Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 123.54 | 113.735 | 58.763 | 28.109 | 14.975 |
| Selling/General/Admin. Expenses, Total | 30.651 | 26.957 | 10.586 | 3.83 | 2.354 |
| Research & Development | 92.889 | 86.778 | 48.177 | 24.279 | 12.621 |
| Operating Income | -123.54 | -113.735 | -58.763 | -28.109 | -14.975 |
| Other, Net | 8.102 | 2.041 | 1.834 | 0.539 | 0.295 |
| Net Income Before Taxes | -115.438 | -111.694 | -56.929 | -27.57 | -14.68 |
| Net Income After Taxes | -115.438 | -111.694 | -56.929 | -27.57 | -14.68 |
| Net Income Before Extra. Items | -115.438 | -111.694 | -56.929 | -27.57 | -14.68 |
| Net Income | -115.438 | -111.694 | -56.929 | -27.57 | -14.68 |
| Income Available to Common Excl. Extra. Items | -115.438 | -111.694 | -56.929 | -27.57 | -14.68 |
| Income Available to Common Incl. Extra. Items | -115.438 | -111.694 | -56.929 | -27.57 | -14.68 |
| Diluted Net Income | -115.438 | -111.694 | -56.929 | -27.57 | -14.68 |
| Diluted Weighted Average Shares | 47.3716 | 46.0498 | 12.4785 | 4.27042 | 4.27042 |
| Diluted EPS Excluding Extraordinary Items | -2.43686 | -2.42551 | -4.56218 | -6.45603 | -3.4376 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -2.43686 | -2.42551 | -4.56218 | -6.45603 | -3.4376 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 32.398 | 29.115 | 33.385 | 30.406 | 29.461 |
| Selling/General/Admin. Expenses, Total | 7.432 | 7.281 | 7.516 | 7.517 | 8.151 |
| Research & Development | 24.966 | 21.834 | 25.869 | 22.889 | 21.31 |
| Operating Income | -32.398 | -29.115 | -33.385 | -30.406 | -29.461 |
| Other, Net | 1.967 | 1.397 | 4.744 | 0.448 | 2.087 |
| Net Income Before Taxes | -30.431 | -27.718 | -28.641 | -29.958 | -27.374 |
| Net Income After Taxes | -30.431 | -27.718 | -28.641 | -29.958 | -27.374 |
| Net Income Before Extra. Items | -30.431 | -27.718 | -28.641 | -29.958 | -27.374 |
| Net Income | -30.431 | -27.718 | -28.641 | -29.958 | -27.374 |
| Income Available to Common Excl. Extra. Items | -30.431 | -27.718 | -28.641 | -29.958 | -27.374 |
| Income Available to Common Incl. Extra. Items | -30.431 | -27.718 | -28.641 | -29.958 | -27.374 |
| Diluted Net Income | -30.431 | -27.718 | -28.641 | -29.958 | -27.374 |
| Diluted Weighted Average Shares | 56.2405 | 47.7372 | 47.6892 | 47.4498 | 47.2767 |
| Diluted EPS Excluding Extraordinary Items | -0.54109 | -0.58064 | -0.60058 | -0.63136 | -0.57902 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.54109 | -0.58064 | -0.60058 | -0.63136 | -0.57902 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 204.38 | 295.115 | 220.809 | 20.224 | 15.595 |
| Cash and Short Term Investments | 201.728 | 291.233 | 218.309 | 18.879 | 15.595 |
| Cash & Equivalents | 30.605 | 31.828 | 218.309 | 18.879 | 15.595 |
| Prepaid Expenses | 2.652 | 3.882 | 2.5 | 1.345 | 0 |
| Total Assets | 220.5 | 305.098 | 223.59 | 21.871 | 16.406 |
| Property/Plant/Equipment, Total - Net | 6.7 | 5.636 | 2.48 | 1.647 | 0.811 |
| Property/Plant/Equipment, Total - Gross | 10.019 | 7.634 | 3.563 | 2.203 | 1.002 |
| Accumulated Depreciation, Total | -3.319 | -1.998 | -1.083 | -0.556 | -0.191 |
| Total Current Liabilities | 21.702 | 19.201 | 11.375 | 4.835 | 2.447 |
| Accounts Payable | 6.777 | 7.84 | 3.92 | 1.974 | 1.362 |
| Accrued Expenses | 14.401 | 11.274 | 7.035 | 2.289 | 1.026 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.258 | 0 | ||
| Other Current Liabilities, Total | 0.524 | 0.087 | 0.42 | 0.314 | 0.059 |
| Total Liabilities | 25.063 | 19.201 | 11.407 | 4.84 | 2.504 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 3.361 | 0 | 0.032 | 0.005 | 0.057 |
| Total Equity | 195.437 | 285.897 | 212.183 | 17.031 | 13.902 |
| Redeemable Preferred Stock | 0 | 66.443 | 36.595 | ||
| Common Stock | 0.005 | 0.005 | 0.004 | 0 | 0 |
| Additional Paid-In Capital | 531.682 | 505.723 | 319.605 | 1.085 | 0.234 |
| Retained Earnings (Accumulated Deficit) | -334.558 | -219.12 | -107.426 | -50.497 | -22.927 |
| Total Liabilities & Shareholders’ Equity | 220.5 | 305.098 | 223.59 | 21.871 | 16.406 |
| Total Common Shares Outstanding | 47.899 | 47.6023 | 43.7057 | 4.27042 | 4.27042 |
| Other Long Term Assets, Total | 9.42 | 4.347 | 0.301 | ||
| Short Term Investments | 171.123 | 259.405 | |||
| Other Equity, Total | -1.692 | -0.711 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 234.916 | 260.21 | 175.263 | 204.38 | 226.893 |
| Cash and Short Term Investments | 230.506 | 254.989 | 172.255 | 201.728 | 224.043 |
| Cash & Equivalents | 15.896 | 26.446 | 18.201 | 30.605 | 52.022 |
| Prepaid Expenses | 4.41 | 5.221 | 3.008 | 2.652 | 2.85 |
| Total Assets | 258.511 | 280.611 | 198.32 | 220.5 | 242.327 |
| Property/Plant/Equipment, Total - Net | 7.082 | 7 | 6.731 | 6.7 | 6.464 |
| Other Long Term Assets, Total | 16.513 | 13.401 | 16.326 | 9.42 | 8.97 |
| Total Current Liabilities | 16.893 | 15.19 | 19.662 | 21.702 | 21.56 |
| Accounts Payable | 5.17 | 5.585 | 7.082 | 6.777 | 10.25 |
| Accrued Expenses | 10.904 | 8.796 | 11.692 | 14.401 | 11.135 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.819 | 0.809 | 0.888 | 0.524 | 0.175 |
| Total Liabilities | 20.254 | 18.551 | 23.023 | 25.063 | 24.92 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 3.361 | 3.361 | 3.361 | 3.361 | 3.36 |
| Total Equity | 238.257 | 262.06 | 175.297 | 195.437 | 217.407 |
| Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.005 |
| Additional Paid-In Capital | 662.172 | 655.473 | 537.966 | 531.682 | 525.682 |
| Retained Earnings (Accumulated Deficit) | -423.315 | -392.707 | -362.276 | -334.558 | -305.917 |
| Total Liabilities & Shareholders’ Equity | 258.511 | 280.611 | 198.32 | 220.5 | 242.327 |
| Total Common Shares Outstanding | 54.8157 | 54.8087 | 47.9163 | 47.899 | 47.8468 |
| Short Term Investments | 214.61 | 228.543 | 154.054 | 171.123 | 172.021 |
| Other Equity, Total | -0.605 | -0.711 | -0.398 | -1.692 | -2.363 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -115.438 | -111.694 | -56.929 | -27.57 | -14.68 |
| Cash From Operating Activities | -83.729 | -83.531 | -46.177 | -25.665 | -12.954 |
| Cash From Operating Activities | 1.324 | 0.915 | 0.542 | 0.382 | 0.149 |
| Non-Cash Items | 29.453 | 23.623 | 5.594 | 0.856 | 0.195 |
| Changes in Working Capital | 0.932 | 3.625 | 4.616 | 0.667 | 1.382 |
| Cash From Investing Activities | 81.691 | -263.803 | -0.621 | -0.78 | -0.529 |
| Capital Expenditures | -3.019 | -2.323 | -0.621 | -0.78 | -0.529 |
| Cash From Financing Activities | 0.815 | 164.897 | 246.228 | 29.729 | 17.937 |
| Issuance (Retirement) of Stock, Net | 0.815 | 165.2 | 246.498 | 29.853 | 17.937 |
| Issuance (Retirement) of Debt, Net | -0.258 | -0.124 | 0 | ||
| Net Change in Cash | -1.223 | -182.437 | 199.43 | 3.284 | 4.454 |
| Financing Cash Flow Items | 0 | -0.303 | -0.012 | ||
| Other Investing Cash Flow Items, Total | 84.71 | -261.48 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -27.718 | -115.438 | -86.797 | -56.839 | -29.465 |
| Cash From Operating Activities | -30.134 | -83.729 | -60.802 | -40.363 | -21.895 |
| Cash From Operating Activities | 0.278 | 1.324 | 0.962 | 0.625 | 0.307 |
| Non-Cash Items | 6.242 | 29.453 | 23.35 | 15.483 | 7.988 |
| Changes in Working Capital | -8.936 | 0.932 | 1.683 | 0.368 | -0.725 |
| Cash From Investing Activities | 17.999 | 81.691 | 80.336 | 58.729 | 41.548 |
| Capital Expenditures | -0.81 | -3.019 | -2.626 | -1.71 | -0.952 |
| Cash From Financing Activities | -0.269 | 0.815 | 0.66 | 0.512 | 0.153 |
| Issuance (Retirement) of Stock, Net | 0.028 | 0.815 | 0.66 | 0.512 | 0.153 |
| Issuance (Retirement) of Debt, Net | |||||
| Net Change in Cash | -12.404 | -1.223 | 20.194 | 18.878 | 19.806 |
| Other Investing Cash Flow Items, Total | 18.809 | 84.71 | 82.962 | 60.439 | 42.5 |
| Financing Cash Flow Items | -0.297 | 0 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 19.9042 | 10909256 | 0 | 2023-06-30 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 18.4712 | 10123824 | 0 | 2023-06-30 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 6.8666 | 3763500 | 971405 | 2023-06-30 | LOW |
| Vaddi (Krishna) | Individual Investor | 4.9539 | 2715145 | 13756 | 2023-05-25 | LOW |
| Boxer Capital, L.L.C. | Hedge Fund | 4.5522 | 2495018 | 1795971 | 2023-06-30 | LOW |
| UBS Asset Management (Switzerland) | Investment Advisor | 4.1488 | 2273894 | -62050 | 2023-03-31 | LOW |
| Fidelity Institutional Asset Management | Investment Advisor | 3.9715 | 2176720 | 422137 | 2023-06-30 | LOW |
| EcoR1 Capital, LLC | Hedge Fund | 2.1118 | 1157452 | 1157452 | 2023-06-30 | LOW |
| UBS Asset Management (Americas), Inc. | Investment Advisor | 1.9596 | 1074037 | -929857 | 2023-06-30 | LOW |
| T. Rowe Price Associates, Inc. | Investment Advisor | 1.9452 | 1066143 | 795881 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.7387 | 952938 | 36924 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.4325 | 785115 | 390296 | 2023-06-30 | LOW |
| MFS Investment Management | Investment Advisor/Hedge Fund | 0.9294 | 509390 | -5158 | 2023-06-30 | LOW |
| Friedman (Paul A) | Individual Investor | 0.9124 | 500098 | 0 | 2023-03-31 | LOW |
| Combs (Andrew P) | Individual Investor | 0.5605 | 307207 | 2765 | 2023-03-31 | LOW |
| Woodline Partners LP | Hedge Fund | 0.4525 | 248000 | 248000 | 2023-06-30 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4421 | 242294 | 96390 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3354 | 183809 | 139920 | 2023-06-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.3344 | 183300 | 44800 | 2023-06-30 | HIGH |
| Scherle (Peggy A) | Individual Investor | 0.3205 | 175685 | 175685 | 2023-03-31 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Prelude Therapeutics Incorporated Company profile
About Prelude Therapeutics Inc
Prelude Therapeutics Inc. is a clinical-stage precision oncology company. The Company is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. The Company is developing therapies in both solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT-K4.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Prelude Therapeutics Inc revenues was not reported. Net loss increased 96% to $111.7M. Higher net loss reflects Research and development increase of 70% to $77.3M (expense), Stock-based Compensation in SGA increase from $3M to $11.5M (expense), General and administrative - Balancing increase from $7.6M to $15.5M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
200 Powder Mill Road
WILMINGTON
DELAWARE 19803
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com